ArticleFrontiers in pharmacology2026
Case Report: zanidatamab-based regimen as a potential later-line therapeutic option in HER2-amplified metastatic colorectal cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Overexpression human epidermal growth factor receptor 2 (HER-2) has been identified as a key oncogenic driver in metastatic colorectal cancer (mCRC), detected in between 2% and 5% of the overall mCRC population, with a higher prevalence identified in RAS/RAF/PI3KCA wild-type patients. Optimal targeted interventions are seldom administered to patients with HER2-positive mCRC due to the absence of definitive anti-HER2 therapeutic regimens in the refractory setting. As a result, for patients who have undergone multiple lines of therapy-particularly those with cetuximab resistance driven by ERBB2 amplification-mediated bypass activation-treatment strategies are frequently confined to best palliative care or participation in clinical trials. Case presentation: This report demonstrates a case of multi-line refractory mCRC with high-level HER2 overexpression. Following multi-line treatment therapies, the patient was treated with a zanidatamab-based chemotherapy salvage regimen, leading to a partial response (PR) and an ongoing progression-free survival of approximately 10 months. Conclusion: This case study highlights that the combination of zanidatamab with liposomal irinotecan and raltitrexed may provide an encouraging anti-tumor therapeutic option for mCRC patients with extremely high-level HER-2 overexpression and resistance to conventional anti-EGFR therapies. These findings offer valuable clinical insights into combining bispecific anti-HER2 targeted therapy with an optimized chemotherapy backbone, warranting further evaluation in prospective trials. Nevertheless, future prospective trials with larger cohorts are warranted to establish its survival benefits and universal applicability definitively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.